138

SIMPLE NOMOGRAM TO PREDICT 30-DAY READMISSION WITH RECURRENT VARICEAL BLEEDING IN LIVER CIRRHOSIS PATIENTS USING SUPERVISED MACHINE LEARNING FROM UNITED STATES POPULATION

Date
May 6, 2023
Explore related products in the following collection:

Society: AGA

Introduction:
Acute variceal bleeding (AVB) is a major cause of death in cirrhotic patients. We developed and internally validated a pragmatic model to predict the individualized risk of 30-day readmission with recurrent AVB in liver cirrhosis patients.

Methods:
Hospitalizations with a primary diagnosis of esophageal AVB were identified using the 2019's Nationwide Readmission Database (NRD). We utilized the NRD as it recognizes the same patient's index admissions and recognition of readmissions. Patients were excluded if aged <18 years, had non-AVB, end-stage renal disease, solid organ transplants, anticoagulation use, immunosuppression, para/quadriplegics, lymphomas/leukemias, or malignant tumors. We used supervised machine learning to input variables with increased association with recurrent AVB readmissions to undergo Least Absolute Shrinkage and Selection Operator (LASSO) penalized regression for selecting the best predictors. Receiver operating characteristic (ROC) curves assessed predictive power for each selected predictor and those with a poor threshold of discrimination [area under the curve (AUC <0.60)] were eliminated. The remaining predictors were utilized to develop a variceal AVB nomogram. The nomogram was internally validated using 10 fold cross validation, and ROC curves were generated along with bootstrapped Bias corrected (BC) 95% confidence intervals (CI) for the AUC. The Brier score was used to report measures of overall performance.

Results:
The prevalence of recurrent AVB readmissions was 2.65%. For the model predicting the risk, five predictors were included: Chronic pulmonary disease history (AUC 0.84± 0.003 ), Age >=50 years (AUC 0.61 ± 0.002), Transjugular intrahepatic portosystemic shunt (TIPS) during index hospitalization (AUC 0.89±0.003 ), Obesity (AUC 0.84± 0.002), history of cardiac arrhythmia (AUC 0.84± 0.002) (Figure 1). These variables were used to develop a nomogram that displayed outstanding discrimination AUC 0.91 (Bootstrap Bias Corrected 95%CI 0.90-0.92), correlating to a 91% probability of the model correctly assigning a higher score to patients at risk of recurrent variceal bleed readmission within 30 days of discharge (Figure 2A, 2B). Liu's index was used to determine the cut-off (21 points). Therefore patients with a score ≥ 21 were deemed at high risk for recurrent AVB readmission. For high-risk patients, with a sensitivity of 80.44% and a negative predictive value of 99.47%, the specificity was 100.00% with a positive predictive value of 100.00%. The Brier score was 0.005, indicating the good overall performance of the nomogram.

Conclusions:
The proposed nomogram score can be used to identify such patients with a risk for recurrent variceal bleed readmission within 30 days of discharge.
<b>Figure 1: </b>Individual Receiver operating characteristic (ROC) curves of selected predictors by penalized regression (LASSO) with acceptable discriminative power (ROC curve >0.60)

Figure 1: Individual Receiver operating characteristic (ROC) curves of selected predictors by penalized regression (LASSO) with acceptable discriminative power (ROC curve >0.60)

<b>Figure 2: </b>(A) The proposed risk nomogram; (B) ROC curve with mean cross validated area under the curve (CvAUC) after 10 fold cross validation. AUC: 0.91 (Bootstrap Bias Corrected 95%CI 0.90-0.92)

Figure 2: (A) The proposed risk nomogram; (B) ROC curve with mean cross validated area under the curve (CvAUC) after 10 fold cross validation. AUC: 0.91 (Bootstrap Bias Corrected 95%CI 0.90-0.92)


Tracks

Related Products

Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for ACTIVATING TRANSCRIPTION FACTOR 6 ACCELERATES MICROBIOTA-DEPENDENT RISK FOR COLITIS-ASSOCIATED CANCER IN INFLAMMATORY BOWEL DISEASES
ACTIVATING TRANSCRIPTION FACTOR 6 ACCELERATES MICROBIOTA-DEPENDENT RISK FOR COLITIS-ASSOCIATED CANCER IN INFLAMMATORY BOWEL DISEASES
BACKGROUND AND AIMS: Chemoresistance is a major cause of colorectal cancer (CRC) recurrence and death. The critical role of gut microbiome in the efficacy of CRC chemotherapy remains unclear…
Thumbnail for A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…